Home » U.S. FDA Crafting Risk-Benefit Decisionmaking Scheme, Pilot Underway
U.S. FDA Crafting Risk-Benefit Decisionmaking Scheme, Pilot Underway
January 10, 2012
The U.S. Food and Drug Administration (FDA) is using a decisionmaking matrix to weigh expected clinical benefits for biopharmaceuticals against their risks in a pilot program using six new molecular entity applications under review.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor